VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
194.70
+4.18 (+2.19%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close190.52
Open192.63
Bid189.12 x 900
Ask194.99 x 1400
Day's Range189.41 - 194.78
52 Week Range144.07 - 194.92
Volume2,149,793
Avg. Volume1,576,639
Market Cap49.757B
Beta (3Y Monthly)1.51
PE Ratio (TTM)77.79
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Vertex Pharmaceuticals Begins Forming A Base
    Investor's Business Daily Video7 days ago

    Vertex Pharmaceuticals Begins Forming A Base

    Vertex Pharmaceuticals Begins Forming A Base

  • Markit4 days ago

    See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.

    # Vertex Pharmaceuticals Inc ### NASDAQ/NGS:VRTX View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for VRTX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting VRTX. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. ETFs that hold VRTX had net inflows of $12.22 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Where Will CRISPR Therapeutics Be in 10 Years?
    Motley Fool6 days ago

    Where Will CRISPR Therapeutics Be in 10 Years?

    This gene-editing biotech could boom or bust over the next decade. But one potential future seems much more likely.

  • 3 Biotech Stocks to Watch in 2019
    Motley Fool7 days ago

    3 Biotech Stocks to Watch in 2019

    Clinical-trial and regulatory-review decisions make these three drug developers worth keeping tabs on this year.

  • Stocks Pare Losses As Small Caps Lead; Why Netflix Led The IBD 50
    Investor's Business Daily7 days ago

    Stocks Pare Losses As Small Caps Lead; Why Netflix Led The IBD 50

    The major stock indexes ended a four-day win streak but losses were minor, while Netflix showed new signs of rising from its deep slump.

  • Why This IBD Stock Of The Day Broke Out Despite Biotech Turbulence
    Investor's Business Daily7 days ago

    Why This IBD Stock Of The Day Broke Out Despite Biotech Turbulence

    Vertex Pharmaceuticals is the IBD Stock Of The Day as the leading biotech stock broke out in above-average volume The biotech is a leader in treatments for cystic fibrosis, a lung disease.

  • Moderna (MRNA) Announces Pipeline Progress, Shares Rise
    Zacks10 days ago

    Moderna (MRNA) Announces Pipeline Progress, Shares Rise

    Modern's pipeline of mRNA candidates, which are being developed for several cancer indications and rare diseases, is progressing well.

  • Markit10 days ago

    See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.

    # Vertex Pharmaceuticals Inc ### NASDAQ/NGS:VRTX View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for VRTX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting VRTX. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding VRTX are favorable, with net inflows of $16.68 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Is Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) CEO Being Overpaid?
    Simply Wall St.11 days ago

    Is Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) CEO Being Overpaid?

    Jeffrey Leiden has been the CEO of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) since 2012. First, this article will compare CEO compensation with compensation at other large companies. After that, we will Read More...

  • Why CRISPR Therapeutics Stock Rose ~13.05% Yesterday
    Market Realist11 days ago

    Why CRISPR Therapeutics Stock Rose ~13.05% Yesterday

    Why CRISPR Therapeutics Stock Rose ~13.05% Yesterday ## CRISPR’s performance On January 7, CRISPR Therapeutics (CRSP) stock rose ~13.05% to $34.22 from its previous close of $30.27 on January 4. On January 4, CRISPR Therapeutics stock rose ~8.03% to $30.27 from its previous close of $28.02 on January 3. On January 7, CRISPR closed ~54% up from its 52-week low of $22.22 on December 21, 2018. The company hit its 52-week high of $73.90 on May 24, 2018. ## Reason for the stock price hike On January 4, the FDA granted a fast track designation to CRISPR Therapeutics and Vertex Pharmaceuticals’ (VRTX) CTX001 for the treatment of individuals with sickle cell disease. The FDA’s fast track designation will help Vertex and CRISPR with several benefits, including the more frequent scheduling of meetings and communication with the FDA. The fast track designation will also allow the companies to file for the accelerated approval or priority review of their biologics license applications. Right now, CRISPR Therapeutics and Vertex Pharmaceuticals are enrolling patients in Phase 1 and Phase 2 trials for the evaluation of CTX001 for the treatment of individuals with sickle cell disease. ## Analysts’ recommendations Of the 11 analysts tracking CRISPR Therapeutics in January, one has recommended a “strong buy,” while six have recommended “buys” on the stock. Three analysts have recommended “holds,” while one has recommended a “sell” on the stock. On January 7, CRISPR Therapeutics had a consensus 12-month target price of $63.72, which represents a potential ~86.21% return on investment over the next 12 months.

  • Markit11 days ago

    See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.

    # Vertex Pharmaceuticals Inc ### NASDAQ/NGS:VRTX View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is extremely low for VRTX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting VRTX. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding VRTX are favorable, with net inflows of $16.68 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 5 Things to Expect for Vertex Pharmaceuticals in 2019
    Motley Fool11 days ago

    5 Things to Expect for Vertex Pharmaceuticals in 2019

    CEO Jeff Leiden told the audience at the J.P. Morgan Healthcare Conference exactly what the biotech plans to achieve this year.

  • A Look at Sarepta Therapeutics’ Recent Developments
    Market Realist11 days ago

    A Look at Sarepta Therapeutics’ Recent Developments

    Who Is Eyeing Sarepta Therapeutics Now? (Continued from Prior Part) ## Earnings trends In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year. In the third quarter of 2018, the company reported net income and EPS of -$76.4 million and -$1.15, respectively, compared to -$47.7 million and -$0.78 in the third quarter of 2017. Wall Street analysts anticipate that in the fourth quarter of 2018, Sarepta Therapeutics will report net income and EPS of -$63.26 million and -$0.95, respectively. Analysts also estimate that the company will report net income and EPS of -$274.73 million and -$4.16, respectively, in fiscal 2018. Wall Street analysts estimate that BioMarin Pharmaceuticals (BMRN), Nektar Therapeutics (NKTR), and Vertex Pharmaceuticals (VRTX), Sarepta Therapeutics’ peers in the biopharmaceuticals market, will report EPS of around -$0.62, $3.88, and $2.88, respectively, in fiscal 2018. ## Recent developments On January 2, 2019, Sarepta Therapeutics entered a long-term strategic relationship with Aldevron. Aldevron is one of the leading producers of custom proteins, nucleic acids, and antibodies for use in the biotech industry. As per the terms of the agreement, Aldevron will supply plasmid DNA for the fulfillment of Sarepta Therapeutics’ requirements in its gene therapy clinical trials and commercial purposes. Aldevron will specifically supply GMP-grade plasmid for Sarepta Therapeutics’ micro-dystrophin Duchenne muscular dystrophy (or DMD) and Limb-girdle muscular dystrophy (or LGMD) gene therapy programs. As per the terms of the agreement, Aldevron will also supply plasmid for Sarepta Therapeutics’ future gene therapy programs. The agreement is expected to help Sarepta Therapeutics with sufficient plasmid for research and commercial purposes. Browse this series on Market Realist: * Part 1 - Sarepta Therapeutics Stock Rose 96% in 2018 * Part 2 - How Is Sarepta Therapeutics Positioned in January?

  • How Is Sarepta Therapeutics Positioned in January?
    Market Realist11 days ago

    How Is Sarepta Therapeutics Positioned in January?

    Who Is Eyeing Sarepta Therapeutics Now? (Continued from Prior Part) ## Revenue trends In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million. In the third quarter of 2018, the company’s revenue grew ~71% YoY to $78.5 million from $46.0 million. Wall Street analysts estimate that Sarepta Therapeutics will generate revenues of $85.8 million in the fourth quarter of 2018. Analysts also estimate that the company’s net revenue in fiscal 2018 will be around $301.1 million, which represents ~49.9% YoY growth. In the third quarter of 2018, Nektar Therapeutics (NKTR), Vertex Pharmaceuticals (VRTX), and BioMarin Pharmaceuticals (BMRN), Sarepta Therapeutics’ peers in the biopharmaceuticals market, reported revenues of $27.8 million, $783.9 million, and $391.7 million, respectively, which represents a ~81.9% YoY decline, a ~42.04% YoY increase, and a ~17.23% YoY increase. Wall Street analysts estimate that Nektar Therapeutics (NKTR), Vertex Pharmaceuticals (VRTX), and BioMarin Pharmaceuticals (BMRN) will generate revenues of $1.2 billion, $3.0 billion, and $1.5 billion, respectively, which represents ~289%, ~37.41%, and ~15% YoY growth. ## Expense trends In the first nine months of 2018, Sarepta Therapeutics’ cost of sales excluding amortization of in-licensed rights amounted to $21.1 million compared to $3.8 million in the same period the prior year. In the first nine months of 2018, Sarepta Therapeutics reported R&D (research and development) and SG&A (selling, general, and administrative) expenses of $255.6 million and $143.5 million, respectively, compared to $122.3 million and $90.5 million in the same period the prior year. Wall Street analysts estimate that Sarepta Therapeutics will report cost of sales, SG&A, and R&D expenses of $30.2 million, $190.88 million and $317.02 million, respectively, in fiscal 2018. Continue to Next Part Browse this series on Market Realist: * Part 1 - Sarepta Therapeutics Stock Rose 96% in 2018 * Part 3 - A Look at Sarepta Therapeutics’ Recent Developments

  • Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag
    Zacks12 days ago

    Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag

    FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for the treatment of sickle cell disease.

  • Outlook For Battered Biotech Stocks In 2019
    Investopedia13 days ago

    Outlook For Battered Biotech Stocks In 2019

    Biotech stocks, which have fallen 20% from last year's high based on the iShares Nasdaq Biotechnology ETF (IBB), could face more declines in the year ahead. A combination of negative headwinds including weak sales growth, earnings revisions and other forces are likely to plague the once-red hot sector.

  • Better Buy: CRISPR Therapeutics vs. Vertex Pharmaceuticals
    Motley Fool13 days ago

    Better Buy: CRISPR Therapeutics vs. Vertex Pharmaceuticals

    These biotech partners are collaborating on the same project, but which is better positioned to perform for investors?

  • Markit14 days ago

    See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting VRTX. According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy
    Investor's Business Daily14 days ago

    These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy

    Crispr Therapeutics popped Friday after the FDA said it would expedite review of its Vertex Pharmaceuticals-partnered gene-editing sickle cell disease treatment.

  • Vertex Joins Forces With Arbor to Build Gene-Editing Therapies
    Zacks15 days ago

    Vertex Joins Forces With Arbor to Build Gene-Editing Therapies

    Vertex (VRTX) inks a collaboration deal with small biotech entity Arbor to discover novel proteins for progressing discovery of gene-editing therapies to tackle serious ailments.

  • Vertex teams up with Feng Zhang startup on gene editing tech
    American City Business Journals16 days ago

    Vertex teams up with Feng Zhang startup on gene editing tech

    Zhang, a core member of the Broad Institute, played a leading role in developing the gene editing tool CRISPR/Cas9.

  • Could This New Biotech IPO Could Score Big With A Cancer Vaccine?
    Investor's Business Daily16 days ago

    Could This New Biotech IPO Could Score Big With A Cancer Vaccine?

    An analyst initiated coverage of Moderna stock Wednesday with a buy rating, saying he expects the biotech to have an approved drug in 2024. Moderna is working in messenger RNA, or mRNA.

  • Benzinga23 days ago

    6 Valuable Pipeline Drugs With Upcoming Catalysts

    Heading into December, biotech stocks held up fairly well in 2018. Evaluate Pharma , a firm specializing in data-driven news and analysis in biotech, compiled a list of blockbuster drugs in the works with ...

  • Benzinga23 days ago

    HC Wainwright Bullish On Corbus Therapeutics' Cystic Fibrosis Opportunity

    Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) has Phase 3 trials ongoing for its lead compound lenabasum in systemic sclerosis and dermatomyositis, and Phase 2 trials for cystic fibrosis and systemic ...

  • See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.
    Markit28 days ago

    See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting VRTX. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.